FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys ...

World-renowned stem cell scientists will gather in Kyoto, Japan for the International Society for Stem Cell Research (ISSCR) ...

Peptide Therapeutics Market was valued at USD 47.2 Million in 2023, and is expected to reach USD 93.0 Million in 2033, at a CAGR of 7.2% NEW Y ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...

Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Rapid growth fueled by advances in stem cell research and gene editing technologies. Cell Therapy Regenerative Medicine Market growth was valued at 45.46 Billion USD in 2023. Cell Therapy Regenerative ...

Beacon Therapeutics Holdings Limited ('Beacon Therapeutics' or 'the Company'), a leading ophthalmic gene therapy company with ...

The rapid advancements in regenerative medicine (RM), including cell therapies ... This paper reviews the regulatory frameworks for RM across the United States, European Union, Japan, Canada, ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

These companies valuations have fluctuated since - Exelixis' is now valued at $10.65bn, Genmab, $13.7bn, Alnylam, $32.4bn, BioMarin, $11.7bn, and United Therapeutics, $16.1bn, while Sarepta's ...